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Abstract
Background: Drug resistance has been a cause of concern for tuberculosis (TB) control in both developed and
developing countries. Careful monitoring of the patterns and trends of drug resistance should remain a priority.
Methods: Strains were collected from 1824 diagnosed sputum smear positive pulmonary TB patients in Jiangsu
province of China and then tested for drug susceptibility against rifampicin, isoniazid, ethambutol and streptomycin.
The prevalence and patterns of drug resistance in mycobacterium tuberculosis (MTB) isolates were investigated.
Multiple logistic regression analysis was performed to identify the risk factors for multidrug resistant (MDR) bacterial
infection. The strength of association was estimated by odds ratio (OR) and 95% confidence interval (95% CI).
Results: The drug susceptibility tests showed that 1077(59.05%) MTB strains were sensitive to all the four
antibiotics and the other 747(40.95%) strains were resistant to at least one drug. The proportions of mono-drug
resistance were 28.73% for isoniazid, 19.41% for rifampicin, 29.33% for streptomycin, and 13.98% for ethambutol,
respectively. The prevalence of MDR-TB was 16.61%, which was significantly different between new cases (7.63%)
and those with previous treatment history (33.07%). Geographical variation of drug resistance was observed, where
the proportion of MDR-TB among new cases was higher in the central (9.50%) or north part (9.57%) than that in
the south area (4.91%) of Jiangsu province. The age of patients was significantly associated with the risk of drug
resistance (P < 0.001) and the adjusted OR (95% CI) was 1.88(1.26-2.81) for patients aged 35-44 years when
compared with those 65 years or older. Patients with previous treatment history had a more than 5-fold increased
risk of MDR-TB (adjusted OR: 6.14, 95% CI: 4.61-8.17), compared with those previously not having been treated.
Conclusions: The high prevalence of drug resistance has been a major challenge for TB control. Prevention and
control of drug-resistant TB should be emphasized by the revised DOTS (direct observed therapy, short course)
program through prompt case detection, routine and quality-assured drug susceptibility test for patients at high
risk of resistance, programmatic treatment with both first and second-line medicines, and systematic treatment
observation, with priority for high MDR-TB settings.
Background
Tuberculosis (TB) is a leading cause of death in humans
due to an infectious agent (mycobacterium tuberculosis,
MTB) and it remains a major public health burden in
developing countries [1]. Globally, there were an esti-
mated 8.9-9.9 million incident cases of TB in 2008,
most of which occurred in Asia and Africa, with the
first two countries being India and China [2]. The cur-
rent anti-tuberculosis therapies are fraught with pro-
blems, predominantly because of the long-term
treatment and the increasing occurrence of drug resis-
tance [3]. Drug resistance can be simply defined as the
capacity of organisms and their progeny to remain
viable or to multiply in the presence of the concentra-
tion of the drug that would normally destroy or inhibit
cell growth [4]. Drug resistance of MTB was reported
soon after the introduction of anti-tuberculosis drugs in
the last century and now has been a critical threat to
global TB control [5]. One of the particularly dangerous
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as resistance to at least isoniazid and rifampicin, the two
most powerful anti-tuberculosis drugs, because the
treatment of such cases is more complex, lengthy,
expensive, frequently less successful and usually produce
more severe adverse reactions [6]. In 2008, an estimated
390,000-510,000 cases of MDR-TB have emerged glob-
ally [7]. China reported a high proportion of drug resis-
tance with the highest burden of cases in the world, just
following the countries of the former Soviet Union [8].
It was estimated that the prevalence of MDR-TB was
5.7% among new cases and 25.6% among those pre-
viously treated in China, which confirmed previous esti-
mates that about 100,000 MDR-TB cases emerged
annually [7].
China has reached the global targets for case detection
and treatment success now, but careful monitoring of
the patterns and trends of drug resistance should remain
a priority. In order to obtain insights into the prevalence
and distribution of anti-tuberculosis drug resistance,
China joined the global surveillance project organized
by WHO/IUATLD (World Health Organization/Interna-
tional Union against Tuberculosis and Lung Diseases).
By 2007, 13 out of 31 provinces (without Jiangsu) in
China have been involved in this surveillance system [9].
As a province located along the eastern coast of China,
Jiangsu covers an area of 102.6 thousand square kilo-
metres and contains 13 municipalities and 106 counties
(districts), with a total population of 77 million in 2009.
DOTS (direct observed therapy, short course) strategy
for TB has been introduced in Jiangsu in the 1990s and
been 100% available at the county level by now [10].
However, there are still great challenges facing TB con-
trol, particularly for the early detection and effective
treatment. Unfortunately, until now, no study has been
conducted to investigate the current situation and pat-
terns of drug resistance among TB patients at the pro-
vincial level in Jiangsu.
Therefore, the aim of the present study was to assess
the drug susceptibility patterns of MTB in Jiangsu and
explore potential risk factors for MDR-TB in order to
provide policy-makers with recommendations for better-
organized TB control programs.
Methods
Study population
T h es a m p l i n gm e t h o dr e f e r r e dt ot h e“Guidelines for
surveillance of drug resistance in tuberculosis” devel-
oped by WHO/IUATLD [11]. Thirty counties (districts)
from Jiangsu province were selected systematically and
the sample size was estimated based on the following
parameters: (1) The annual reported new sputum smear
positive (SS+) cases were 23603 and previously treated
SS+ cases were 5524 (based on the surveillance data in
Jiangsu province); (2) The precision was set at 2% for
new cases and 4% for previously treated cases; (3) The
initial mono-drug resistance rate was set at 6% among
new cases and 16% among previously treated cases
based on the proportion of rifampicin resistant isolates
from a pilot study with small sample size (unpublished);
Additionally, the sample size was amplified by taking
into account the design effect of the cluster sampling
method and potential no-response of study subjects.
Finally, the estimated sample size was 2035, which
included 1247 new cases and 788 previously treated
cases. Sixty-seven SS+ patients from each site were
recruited continuously as expected, including 41 new
patients and 26 previously treated patients. The period
of case recruitment was set between May 1, 2008 and
December 31, 2008. All newly registered pulmonary TB
patients with sputum smear positive tests in selected
study sites were eligible for inclusion. Eligible patients
should be continuously recruited since May 1, 2008,
until the sampling site reaches a minimum number of
cases.
Data collection
After obtaining informed consent, a standard question-
naire was completed for each recruited patient to collect
demographic data and the history of treatment. Cases
were classified into new and previously treated ones
based on patient’s self-reports or available medical docu-
ments. The definitions of new/previously treated cases
referred to the WHO guidelines [7,11]. A ‘new case’ was
defined as a newly registered episode of TB in a patient
who, in response to direct questioning, denied having
had any prior anti-tuberculosis treatment (for up to one
month), and in study sites where adequate documenta-
tion was available, for whom there was no evidence of
such history. A ‘previously treated case’ was defined as a
newly registered episode of TB in a patient who, in
response to direct questioning admitted having been
treated for TB for one month or more, or, in study sites
where adequate documentation was available, there was
evidence of such history.
Laboratory test
Three sputum smear samples were collected from each
subject with labelled plastic bottles. The Ziehl-Neelsen hot
staining method was used for sputum smear microscopy
test. The two sputum samples with the highest bacterial
counts were cultured, and one culture was submitted for
drug susceptibility test (DST). Sputum smear microscopy
and culture were performed at the level of county (district)
laboratory while DST was done at the provincial reference
laboratory. The sputum samples were decontaminated
with 4% sodium hydroxide (NaOH), centrifuged, and then
cultured on Lowenstein-Jensen (LJ) culture media. The LJ
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days 3 and 7 to detect contaminations and/or fast growth
of atypical mycobacteria and subsequently every week to
note the growth and the morphology of the colonies. Iden-
tification of MTB was done using the p-nitrobenzoic acid
(PNB) and thiophene carboxylic acid hydrazine (TCH)
resistance test. Growth in LJ medium containing PNB indi-
cates that the bacilli do not belong to the MTB complex.
Species other than MTB were excluded from the current
analysis. DST utilizes the same type of LJ medium and
inoculation methods as culture techniques. LJ medium was
impregnated with isoniazid (INH), rifampicin (RIF), strep-
tomycin (SM), and ethambutol (EMB) according to the
proportion method as recommended by WHO/IUATLD
[8,11]. The concentrations of anti-tuberculosis drugs were
0.2 μg/ml for INH, 40 μg/ml for RIF, 4 μg/ml for SM, and
2 μg/ml for EMB. The growth of colonies in the drug-
containing plate was compared to the control plate as a
proportion. If the bacterial growth on the medium with the
specific drug was ≥1% compared to the control, the strain
was declared resistant to the specific drug; or it was defined
as sensitive when the growth rate was < 1% compared to
the control. MDR-TB was defined as isolates being resis-
tant to at least RIF and INH. Internal and external quality
controls were conducted through the whole study period.
For internal quality assurance on DST, a standard H37Rv
laboratory strain was included for each batch of culture.
External quality control for sputum smear microscopy and
culture was conducted by the provincial TB reference
laboratory in Jiangsu and further undertaken by the supra-
national reference laboratory of Hong Kong.
Data analysis
Data were double entered with EpiData 3.1 (Denmark)
and discrepancies were checked against the raw data.
T h ep r e v a l e n c eo fm o n o -a n dm u l t i -d r u gr e s i s t a n c e
among new and previously treated TB cases was calcu-
lated. Multiple logistic regression analysis was per-
formed to identify the risk factors for MDR bacterial
infection. Variables included in the final model were
chosen based on the biological plausibility as well as sta-
tistical and epidemiologic criteria. The strength of asso-
ciation was estimated by odds ratio (OR) and 95%
confidence interval (95% CI). All tests of significance
were two sided and a significant threshold was set at
0.05. All analyses were performed using the STATA sta-
tistical software (version 10.0; StataCorp, College Sta-
tion, TX).
Ethical consideration
This project has been approved by Institutional Review
Board of Nanjing Medical University. Written informed
consent was obtained from all participants. Ethics has
been respected throughout the whole study period.
Results
Among 1940 sputum smear positive TB patients
recruited in the study, 1848 (95.26%) cases were posi-
tively cultured, 63 (3.25%) cases were negatively cul-
tured, and 29 (1.49%) cases were contaminated. After
excluding 24 cases infected with non-tuberculosis myco-
bacterium, 1824 cases determined as MTB were
involved in the final analysis (Figure 1). Most of them
(97.81%) were Han Chinese. The nationalities of remain-
ing patients included Hui, Mongolian, Miao, Yi, Zhuang,
Tu, Buyi, Bai, and Hani etc. The average age was 50.8 ±
19.3 years and the sex ratio was 2.7 with 1340 (73.46%)
men and 484 (26.54%) women. Among them, 1180
(64.69%) were new cases and 644 (35.31%) were those
previously treated. The DST results showed that 1077
(59.05%) strains were sensitive to all first-line antibiotics
tested in our study and 747 (40.95%) were resistant to at
least one drug. The proportions of mono-drug resistance
were 28.73% for INH, 19.41% for RIF, 29.33% for SM,
and 13.98% for EMB, respectively (Table 1). Individual
or combined drug resistance to INH, RIF, EMB and SM
was higher in previously treated cases than that in new
cases. The details of multi-drug resistance are presented
in Table 2. Among all isolates, 303(16.61%) strains were
resistant to both INH and RIF (MDR-TB), and 146
(8.00%) strains were resistant to all four first-line anti-
tuberculosis drugs (Table 2, Figure 2). The proportion
of MDR-TB was 33.07% in previously treated cases,
which was significantly higher than that (7.63%) in new
cases (c
2 = 194.76, P < 0.001) (Table 2, Figure 2). We
further divided the study sites into three groups (south,
central and north) based on their locations in Jiangsu
and found the geographical variation of MDR-TB risk
estimates. The proportions of MDR were 13.23% in
south, 18.37% in central and 19.00% in north area of
Jiangsu, respectively (Table 3). The geographical differ-
ence was statistically significant among new cases
(Figure 3). As shown in table 3, a higher proportion of
MDR-TB in new cases was observed in the central or
north part but not in the south area. The percentage of
MDR-TB grouped by age was illustrated in Figure 4.
The frequency of MDR-TB was much higher in young
adults and peaked at 35-44 years old. Compared with
patients aged 65 years or older, the adjusted OR (95%
CI) was 1.88(1.26-2.81) for those aged 35-44 years.
Table 4 showed the number of patients with MDR-TB
and the ORs of potential risk factors. Patients with pre-
vious treatment history had a more than 5-fold
increased risk of MDR-TB (adjusted OR: 6.14, 95% CI:
4.61-8.17), compared with those previously not having
been treated. The risk of MDR-TB for patients living in
the central or north part is more than 1.4-times of that
for those living in the south part, with the ORs of 1.47
(95% CI: 1.01-2.13) and 1.42 (95% CI: 1.05-1.92),
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found between cigarette smoking and the risk of MDR-
TB (OR: 1.01, 95% CI: 0.72-1.42).
Discussion
As a public health dilemma, drug resistance has been an
obstacle to achieve the goal of effective global TB con-
trol. Recently, the emergence of MDR and XDR (exten-
sively drug-resistant) TB has incurred a very alarming
challenge to global health [5,12]. Appreciating the
importance of documenting the drug susceptibility of
MTB, WHO has implemented a worldwide surveillance
programme while findings showed regional and national
variations in the magnitude and trends of drug-resis-
tance [13]. The high prevalence of MDR recently
reported from the expanding number of provinces sur-
veyed in China and Russia is indicative of a larger epi-
demic than previously suspected [6]. In recent years, the
substantial structural transformation of China’s economy
has contributed to the world’s largest ever-peacetime
flow of migration. Mobility of population has been
proved to strengthen the transmission dynamics of TB
as well as antimicrobial drug-resistant organisms
[14,15]. As a more developed eastern province, Jiangsu
absorbed a large proportion of migrations within China.
Now it has been an area with the highest population
density (753 per square kilometre) among all provinces
of China. Exploring the prevalence and pattern of drug
resistance could substantially facilitate the local and
countrywide TB control.
Role of age and sex
In most countries, the majority of TB patients are male
[16]. However, male or female TB patients could have
different levels of risks for drug resistance due to differ-
ences in access to health-care services or exposure to
Figure 1 Flow chart of the study design.
Table 1 Observed mono-drug resistance among tuberculosis cases in Jiangsu Province, China
Category Cases Sensitive Drug resistant
†
At least one drug INH RIF EMB SM
n(%) n(%) n(%) n(%) n(%) n(%)
Total 1824 1077(59.05) 747(40.95) 524(28.73) 354(19.41) 255(13.98) 535(29.33)
New cases 1180 793(67.20) 387(32.80) 228(19.32) 112(9.49) 97(8.22) 287(24.32)
Previously treated cases 644 284(44.10) 360(55.90) 296(45.96) 242(37.58) 158(24.53) 248(38.51)
†: isoniazid (INH); rifampicin (RIF); streptomycin (SM); ethambutol (EMB).
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harboring MDR-TB strains for female was 1.43 (95% CI:
0.99-2.06) compared with male, showing a borderline
association between MDR-TB and the sex of patients.
Discovering gender disparities associated with the risks
of MDR-TB could provide insight into the development
of targeted measures and improve access to health care
and reduce the risk of acquiring drug-resistance. The
association between age and the risk of MDR-TB is not
well established in the literatures as different studies use
different cut-off points for age groups. MDR-TB
patients were more likely to be younger than 65 years
[17,18]. A systematic review analysis in Europe revealed
the pooled risk of MDR-TB for people younger than
45 was higher than that among older patients (OR: 1.52,
95% CI: 1.13-2.03) [17]. In this study, we found that the
frequency of MDR-TB was much higher in young adult-
hoods and peaked at 35-44 years old, which was similar
t ot h ef i n d i n g sf r o mM D R - T Bs u r v e i l l a n c ed a t ai n1 3
countries of Central and Eastern Europe (CEEUR) [7].
This pattern suggests that MDR-TB epidemic in Jiangsu
is a relatively recent phenomenon and bears the highest
toll on young adults. We assum e dt h a ta g e - r e l a t e dd i f -
f e r e n c ei nt r e a t m e n ta d h e r e n c em i g h tb eap o s s i b l e
explanation, as patients at 35-44 years old were often
occupied by study, work or other activities on a daily
basis, in contrast with the more sedentary lifestyle of old
patients [18].
Effect of previous anti-tuberculosis treatment
Drug resistance in MTB isolates arises from spontaneous
genetic mutations and can be amplified through selection
pressure and further exaggerated by poor adherence of
patients [5]. Drug-resistant TB is either acquired due to
poor management of treatment or transmission from infec-
tious drug-resistant TB patients [19]. As found in many
other studies, the history of anti-tuberculosis treatment has
Table 2 Observed multi-drug resistance among
tuberculosis cases in Jiangsu Province, China
Category Cases Drug resistant
† MDR
‡
HR HRE HRS HRSE
n(%) n(%) n(%) n(%) n(%)
Total 1824 37(2.03) 26(1.43) 94(5.15) 146(8.00) 303(16.61)
New cases 1180 9(0.76) 5(0.42) 33(2.80) 43(3.64) 90(7.63)
Previously
treated
cases
644 28(4.35) 21(3.26) 61(9.47) 103(15.99) 213(33.07)
c
2 26.95 23.87 37.98 86.29 194.76
P < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
†: HR: isoniazid+rifampicin; HRE: isoniazid+rifampicin+ethambutol.
HRS: isoniazid+rifampicin+streptomycin.
HRSE: isoniazid+rifampicin+streptomycin+ethambutol.
‡: MDR, resistant to at least isoniazid and rifampicin.
Figure 2 Percentage of drug resistance by treatment history. Drug susceptibility was tested against rifampicin, isoniazid, ethambutol and
streptomycin. MDR: resistant to at least isoniazid and rifampicin.
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A systematic review on 29 studies in Europe reported the
pooled risk of MDR was up to 10 times higher in pre-
viously treated cases than in never treated ones [17]. Our
study is consistent to the former reports that revealed the
importance of previous treatment history in the risk of
drug resistance. These previously treated patients often
constitute a very heterogeneous group including those who
experience relapse after receiving successful treatment,
those who return after default, and those who start receiv-
ing a re-treatment regimen after having experienced pre-
vious treatment failure [21].
Table 3 Observed drug resistance in different areas of Jiangsu Province, China
Area of residence New cases Previously treated cases Total
Cases Resistant
† MDR
‡ Cases Resistant
† MDR
‡ Cases Resistant
† MDR
‡
n(%) n(%) n(%) n(%) n(%) n(%)
South 489 132(26.99) 24(4.91) 229 125(54.59) 71(31.00) 718 257(35.79) 95(13.23)
Central 221 82(37.10) 21(9.50) 122 72(59.02) 42(34.43) 343 154(44.90) 63(18.37)
North 470 173(36.81) 45(9.57) 293 163(55.63) 100(34.13) 763 336(44.04) 145(19.00)
c
2 12.76 8.76 0.65 0.69 13.11 9.84
P 0.002 0.012 0.723 0.708 0.001 0.007
†: Resistant to at least one drug; ‡: MDR, resistant to at least isoniazid and rifampicin.
Figure 3 Geographical variation of MDR-TB in Jiangsu province. The study sites were categorized as three groups (north, central and south)
based on their locations. MDR: resistant to at least isoniazid and rifampicin.
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Geographical variation of drug resistance was observed in
the present study, where a higher proportion of MDR-TB
among new cases was found in the central or north part
as compared with that in the south area. Understanding
the patterns of transmission is important in TB control
because acquired resistance and primary resistance
require different control strategies [22]. To prevent pri-
mary drug resistance, new technologies for early distin-
guishing drug resistance and adopting effective measures
Figure 4 Percentage of MDR-TB by age group. A. Percentage of MDR-TB by age group among all cases. B. Percentage of MDR-TB by age
group among new cases. C. Percentage of MDR-TB by age group among previously treated cases. MDR: resistant to at least isoniazid and
rifampicin. P values were estimated based on the Chi-square test.
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acquired drug resistance, development of high-quality
drugs and strength of patient management are needed
[22]. Lower proportion of primary MDR in the south
part indicates that TB control in this region is rather suc-
cessful and lacks substantial transmission of MDR strains
as compared with the central and north part of Jiangsu.
However, similar higher proportions of acquired drug
resistance among TB patients in these three regions also
cause concerns for strengthening drug development and
patient management. Another interesting topic in the
transmission of MDR-TB is the role of migration, as
Jiangsu is a province absorbing a large number of non-
permanent residents. In this study, we did not specifically
design questions to distinguish the moving population
from the native population. However, one question might
be associated with this topic: “How long have you been
living here"? We analyzed this variable, but found no sig-
nificant association. One possible explanation might be a
large part of moving population preferring to return to
their home when they were suspected as TB. A revised
epidemiological design is needed to further analyze the
role of migration on MDR.
Limitation of this study
Some sources of bias could exist in this study. First, there
is a potential bias in estimation of drug resistance in
previously treated cases. Although we interviewed the
patients, reviewed the medical records and screened the
case notification system to check previous episodes of
TB, we could not exclude the possibility of misclassifica-
tion. Second, we did not perform DST for second-line
anti-tuberculosis drugs in this study. Thus, the preva-
lence of XDR is unclear. Third, there are two most useful
sampling strategies for the surveillance of drug resistance:
100% sampling of diagnostic centres and cluster sampling
[11]. Cluster sampling methods were adopted reasonably
in the situations in which it was logistically difficult to
cover the entire area and where the number of TB diag-
n o s t i cc e n t r e si sh i g h .C l u s t e rs a m p l i n gi sc o m m o n l y
used, rather than simple random sampling, mainly as a
means of saving money when, for example, the popula-
tion is spread out, and the researcher cannot sample
from everywhere. The loss of effectiveness by the use of
cluster sampling, instead of simple random sampling,
should not be neglected. Though in this study, the sam-
ple size was multiplied by the design effect, the higher
sampling error caused by the cluster sampling method
should be taken into account.
Impact
The importance of knowing the susceptibility to MTB
has become more significant because of the increasing
resistance rates, high travel activity of hosts and the
Table 4 Factors associated with multi-drug resistant tuberculosis
Factors Cases No-MDR
† MDR
† cOR(95% CI)
‡ P aOR(95% CI) * P
n = 1824 n = 1521, n(%) n = 303, n(%)
Sex
Men 1340 1129(84.25) 211(15.75) 1 1
Women 484 392(80.99) 92(19.01) 1.26(0.96-1.65) 0.099 1.43(0.99-2.06) 0.058
Age (years)
65+ 547 465(85.01) 82(14.99) 1 1
55-64 298 247(82.89) 51(17.11) 1.17(0.80-1.72) 0.418 1.11(0.74-1.67) 0.602
45-54 276 217(78.62) 59(21.38) 1.54(1.06-2.24) 0.022 1.53(1.03-2.28) 0.035
35-44 270 208(77.04) 62(22.96) 1.69(1.17-2.44) 0.005 1.88(1.26-2.81) 0.002
25-34 188 169(89.89) 19(10.11) 0.64(0.38-1.08) 0.095 0.87(0.49-1.53) 0.626
< 25 245 215(87.76) 30(12.24) 0.79(0.51-1.24) 0.306 1.38(0.84-2.29) 0.206
Treatment history
#
No 1180 1090(92.37) 90(7.63) 1 1
Yes 644 431(66.93) 213(33.07) 5.99(4.57-7.84) < 0.001 6.14(4.61-8.17) < 0.001
Area of residence
South 718 623(86.77) 95(13.23) 1 1
Central 343 280(81.63) 63(18.37) 1.48(1.04-2.09) 0.029 1.47(1.01-2.13) 0.044
North 763 618(81.00) 145(19.00) 1.54(1.16-2.04) 0.003 1.42(1.05-1.92) 0.023
Cigarette smoking
&
Never 862 706(81.90) 156(18.10) 1 1
Ever 954 809(84.80) 145(15.20) 0.81(0.63-1.04) 0.098 1.01(0.72-1.42) 0.942
†:MDR, multidrug-resistant, resistance to at least isoniazid and rifampicin; ‡: cOR, crude odds ratio; *aOR, adjusted odds ratio, adjusted for sex, age, treatment
history, area and cigarette smoking; #:Those having previously received anti-tuberculosis treatment for more than one month was defined as previously treated
cases; &: 8 cases with missing value.
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a crucial intermediate step to allocate resources and
design treatment regimens. However, such population-
based surveys are temporary measures until we know
the drug-susceptibility profile of each patient, which
can be used for prescription of individualized therapy.
DST needs to be scaled up so that patients infected with
susceptible MTB strains can get DOTS, those with
mono-drug resistance can get intensive DOTS to pre-
vent multidrug resistance, and those with MDR can get
the life-saving therapy they need [23]. Unfortunately,
routine DST of MTB is not available at the country
level of China while the laboratories responsible for
diagnosing cases have not been strengthened to meet
these requirements, despite the drug resistance has cap-
tivated the attentions in the past decade. Even in some
health facilities with necessary equipments, the results
of susceptibility test still take more than several weeks,
when the patients with MDR-TB have already been trea-
ted with INH and RIF for quite a long time. Therefore,
new strategies, rapid diagnostic tools [24,25] (such as
molecular line-probe assay), new anti-tuberculosis thera-
pies, and effective vaccines are urgently needed [26].
A better understanding of the risk factors would help to
determine groups of patients who would be more likely
to have MDR-TB and thus prioritize the use of rapid
diagnostic methods for the identification and determina-
tion of drug resistance.
Conclusions
In conclusion, the high prevalence of drug resistance in
Jiangsu province has been a major challenge for TB con-
trol. Patients with previous treatment history are at higher
risk for MDR-TB. Monitoring of drug-resistance should
be enhanced by periodic surveys to assess trends and take
correct actions when necessary. Prevention and control of
drug-resistant TB should be emphasized by the revised
DOTS program through prompt case detection, routine
and quality-assured DST for those patients at high risk of
resistance, programmatic treatment with both first and
second-line medicines, and systematic treatment observa-
tion, with priority for high MDR-TB settings.
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